Literature DB >> 1587746

Carcinoma of the nasopharynx: factors affecting prognosis.

C A Perez1, V R Devineni, V Marcial-Vega, J E Marks, J R Simpson, N Kucik.   

Abstract

This is a retrospective analysis of 143 patients with histologically confirmed epidermoid carcinoma of the nasopharynx treated with definitive irradiation. Patients were treated with a combination of Cobalt-60, 4 to 6 MV X rays, and 18 to 25 MV X rays to the primary tumor and the upper necks, excluding the spinal cord at 4000 to 4500 cGy to total doses of 6000 to 7000 cGy. At 10 years the actuarial primary tumor failure rate was 15% in T1, 25% in T2, 33% in T3, and 60% in T4 lesions. The corresponding failure rate in the neck was 18% for N0, 14% for N1, and 33% for N2 and N3 lymphadenopathy. The incidence of distant metastasis was related to the stage of the cervical lymphadenopathy: 16% in patients with N0-N1 nodes compared with 40% in the N2-3 node group. The actuarial 10-year disease-free survival rate was 55% to 60% for T1-3N0-1 tumors, 45% for T1-3N2-3 tumors, 35% for T4N0-1, and 20% for T4N2-3 lesions. The overall 10-year survival rate was about 40% for patients with T1-2N0-1 tumors, 30% for those with T3 any N stage tumors, and only 10% for the patients with T4 lesions. Multivariate analysis showed that tumor stage and histological type, cranial nerve involvement, patient age, and doses of irradiation to the nasopharynx were significant prognostic factors for local/regional tumor control. Increasing doses of irradiation resulted in nasopharynx tumor control in 80% of the patients receiving 6600 to 7000 cGy and 100% of those receiving over 7000 cGy in the T1, T2, and T3 tumors. However, the tumor control rate did not rise above 55% even for doses over 7000 cGy in the T4 lesions. Local tumor control was higher in patients who had simulation (55/78 = 71%) compared with those on whom simulation was not performed (34/61 = 56%) (p = 0.10). Moreover, patients with more than 75% of the reviewed films judged as adequate had 69% primary tumor control (66/96) compared with 53% (23/43) for those with fewer than 75% adequate portal films (p = 0.07).

Entities:  

Mesh:

Year:  1992        PMID: 1587746     DOI: 10.1016/0360-3016(92)90741-y

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian centres from 1977 to 2000. Part II: Evolving technical choices and toxicity patterns.

Authors:  S M Magrini; S Tonoli; L Costa; N Pasinetti; F Paiar; L Livi; G Simontacchi; I Meattini; L Pegurri; P Borghetti; P Frata; P Ponticelli; M Buglione; G Biti
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

2.  Intensity-modulated radiotherapy for nasopharyngeal carcinoma: improvement of the therapeutic ratio with helical tomotherapy vs segmental multileaf collimator-based techniques.

Authors:  A M Chen; C C Yang; J Marsano; T Liu; J A Purdy
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

3.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

4.  IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.

Authors:  Felix Zwicker; Falk Roeder; Christian Thieke; Carmen Timke; Marc W Münter; Peter E Huber; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

5.  Challenges in the management of nasopharyngeal carcinoma: a review.

Authors:  Baharudin Abdullah; Azila Alias; Shahid Hassan
Journal:  Malays J Med Sci       Date:  2009-10

6.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

7.  Validation of bidimensional measurement in nasopharyngeal carcinoma.

Authors:  Ting-Shou Chang; Sau-Tung Chu; Yu-Yi Hou; Kuo-Ping Chang; Chao-Chuan Chi; Ching-Chih Lee
Journal:  Radiat Oncol       Date:  2010-08-16       Impact factor: 3.481

Review 8.  Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma.

Authors:  Anne W M Lee
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

9.  Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.

Authors:  Kadri Altundag; Sercan Aksoy; Ibrahim Gullu; Ozden Altundag; Enis Ozyar; Suayib Yalcin; Mustafa Cengiz; Fadil Akyol
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

10.  Radiation-induced bilateral optic neuropathy in cancer of the nasopharynx. Case failure analysis and a review of the literature.

Authors:  O B Wijers; P C Levendag; G P Luyten; B A Bakker; N J Freling; J Klesman-Bradley; E Woudstra
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.